The first treatment plan after drug-resistant epilepsy is recognized: agree on changes, monitoring, and referral

At this stage, the patient needs a plan that can be carried out and reviewed. It should identify which medicines continue, what will change, how effects will be observed, and when other treatment assessments begin. An initial plan for established drug resistance builds on previous treatment. It does not mean removing all protection or giving every patient the same new prescription. NICE NG217: Principles of treatment, safety, monitoring and withdrawalJehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

An ongoing prolonged convulsion, repeated events without recovery, or significant breathing or injury concerns belongs in an emergency pathway. Acute treatment and a detailed outpatient plan have different purposes. A prescribed rescue medicine should be used according to the person's established instructions rather than waiting for a comprehensive consultation. NICE NG217: Full guideline, updated January 30, 2025 CDC: First Aid for Seizures
People who may become pregnant, are planning pregnancy, or are already pregnant need early discussion of seizure control, fetal risk, contraception interactions, and folic acid. The 2024 AAN/AES/SMFM guideline emphasizes planning before pregnancy where possible. Abruptly stopping treatment after a positive pregnancy test can increase seizures with risks to both the pregnant person and fetus. AAN/AES/SMFM: Epilepsy and pregnancy guideline, official announcement, May 2024
Before leaving, explain the plan back to the team: what continues now, what happens next, what requires help, and when response will be assessed. If any stage is unclear, request another explanation and an understandable written version. This is a practical requirement for implementing a complex treatment, particularly when care crosses institutions or languages.

Quick answer

At this stage, the patient needs a plan that can be carried out and reviewed. It should identify which medicines continue, what will change, how effects will be observed, and when other treatment assessments begin. An initial plan for established drug resistance builds on previous treatment. It does not mean removing all protection or giving every patient the same new prescription. NICE NG217: Principles of treatment, safety, monitoring and withdrawal Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022

Full guide

At this stage, the patient needs a plan that can be carried out and reviewed. It should identify which medicines continue, what will change, how effects will be observed, and when other treatment assessments begin. An initial plan for established drug resistance builds on previous treatment. It does not mean removing all protection or giving every patient the same new prescription. NICE NG217: Principles of treatment, safety, monitoring and withdrawal Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022

Deal with an acute problem before redesigning chronic care

An ongoing prolonged convulsion, repeated events without recovery, or significant breathing or injury concerns belongs in an emergency pathway. Acute treatment and a detailed outpatient plan have different purposes. A prescribed rescue medicine should be used according to the person's established instructions rather than waiting for a comprehensive consultation. NICE NG217: Full guideline, updated January 30, 2025 CDC: First Aid for Seizures

Events that suddenly increase or change, particularly with fever, memory, or behavioral deterioration, may require prompt investigation of another cause. Infection, metabolic disturbances, or encephalitis can need specific treatment. Not every new change should be attributed automatically to the existing drug-resistant label. Longer-term choices can be organized once urgent concerns are addressed. Abboud et al.: Autoimmune encephalitis diagnosis and acute management best-practice recommendations, 2021

Define what the next change is intended to improve

Separate event types in the diary and explain their consequences. The aim may be complete seizure freedom while also addressing falls, nocturnal tonic-clonic seizures, recovery time, daytime sleepiness, or memory. The clinician needs the patient's priorities to explain the potential value of a proposed change. NINDS: Epilepsy and Seizures

Fewer seizures accompanied by an inability to stay awake does not necessarily represent a satisfactory overall result. Before the adjustment, record what an ordinary day looks like and what prevents work or study. For a child, document development and behavior as well as events. Later comparison is more useful when the baseline is explicit.

Verify previous trials before choosing the starting point

Review the diagnosis, event classification, and whether two adequate suitable schedules truly failed. Incorrect selection, interrupted exposure, and early discontinuation for intolerance need to be distinguished from persistent seizures during an adequate tolerated course. Each provides different information for the next choice. NICE NG217: Terms used, drug-resistant epilepsy definition, updated January 2025 NICE NG217: Diagnosis and assessment of epilepsy

Bring names, strengths, formulations, actual daily use, duration, and stopping reasons. If details are unknown, seek records rather than filling gaps with a guessed maximum dose. An accurate history can prevent repeating an ineffective combination or encountering a previously documented adverse reaction without recognizing it.

Choose for the epilepsy, not for the age or price of the product

Medicines do not cover all seizure types equally. Some choices for focal epilepsy may be unsuitable for particular generalized seizures or childhood syndromes. Conditions such as Dravet require syndrome-informed judgment instead of simply working through a familiar adult focal-epilepsy list. ILAE: Updated classification of epileptic seizures, 2025 NINDS: Dravet Syndrome

The 2026 guideline on third-generation antiseizure medicines evaluates specific evidence and safety considerations. New, imported, or expensive is not evidence that a medicine fits every patient. Check Chinese authorization, age restrictions, and the actual preparation. Inclusion in a guideline discussion does not mean every product is routinely available locally. Wu et al.: Clinical practice guidelines for third-generation antiseizure medications, Seizure 2026;134:13–26 第三代抗癫痫发作药物治疗癫痫的应用指南，中译，癫痫杂志2026;12(3):222–238

Ask the clinician to explain why the proposed option fits this event pattern and what makes it preferable in the patient's circumstances. The explanation may involve safety, interactions, tolerability, or practicality as well as seizure efficacy.

Decide between substitution and an add-on approach

The team may consider replacing a medicine without useful benefit or constructing a rational combination while maintaining needed protection. Additional treatment requires attention to interactions and combined effects on alertness, balance, mood, and cognition. A regimen that remains as straightforward as possible while providing benefit is a reasonable subject for continued review. NICE NG217: Principles of treatment, safety, monitoring and withdrawal

Ask what each medicine is currently contributing and which treatments are temporarily retained for a safe transition. Do not stop a drug independently because it seems ineffective. At the same time, request an explanation if a longstanding combination without clear benefit is being continued. A prescription should remain open to evidence-based review rather than grow by habit.

Make the changeover instructions unambiguous

Substitution can require gradual establishment of the new treatment and withdrawal of the old one according to the particular products and clinical risk. One medicine's taper cannot be copied for another. A serious reaction or acute situation may require a different clinician-directed response. Online dose schedules are not individualized prescriptions. NICE NG217: Principles of treatment, safety, monitoring and withdrawal

Obtain written stages with the exact product, formulation, dates, and contact instructions. When caregivers help administer treatment, check understanding together to avoid following old and new lists at the same time. If several elements change, clarify how the team will distinguish the likely source of benefit or adverse effects.

Match investigations to the actual safety question

Kidney and liver tests, blood counts, ECG, or drug concentrations may be appropriate depending on the medicine and patient. Not everyone needs an identical panel. Normal laboratory results also do not exclude all adverse effects, so symptoms and actual exposure remain part of monitoring. Wu et al.: Clinical practice guidelines for third-generation antiseizure medications, Seizure 2026;134:13–26

China's 2026 lacosamide expert consensus provides drug-specific clinical discussion, illustrating why even familiar medicines require individual assessment. Report cardiac disease, renal problems, and every concurrent treatment before a choice is made. A consensus document should inform the clinician's reasoning rather than become a dose instruction the patient applies independently. 中国抗癫痫协会：拉考沙胺治疗癫痫中国专家共识，2026

Agree where the tests will occur and who will interpret them. If a required investigation is unavailable at home, address that before starting a plan that depends on it. A printed recommendation cannot provide safety unless the necessary response is accessible.

Discuss pregnancy intentions during selection

People who may become pregnant, are planning pregnancy, or are already pregnant need early discussion of seizure control, fetal risk, contraception interactions, and folic acid. The 2024 AAN/AES/SMFM guideline emphasizes planning before pregnancy where possible. Abruptly stopping treatment after a positive pregnancy test can increase seizures with risks to both the pregnant person and fetus. AAN/AES/SMFM: Epilepsy and pregnancy guideline, official announcement, May 2024

The Chinese team should explain options using applicable local labeling and the individual's situation. UK or US regulatory requirements should not be presented as Chinese law, although their safety evidence may inform discussion. The patient should have support in weighing risks rather than being left to choose alone between fear of seizures and fear of medicines.

Treat practical barriers as part of the plan

Missed treatment may reflect shift work, swallowing difficulty, travel, or inability to obtain a prescription. These problems need specific solutions, such as an appropriate preparation, reminders, or a realistic supply arrangement discussed with the clinician. Recording non-adherence without exploring its cause does not solve it. NINDS: Epilepsy and Seizures

For travel, retain identifiable packaging and prescription details and ask in advance about time zones and missed doses. Do not compress the day's treatment into one dose or independently substitute another formulation after crossing a border. A patient seeking care abroad should discuss continued access at home when the new plan is being selected. CDC Yellow Book 2026: Travelers with Chronic Illnesses

Tell the team what has actually happened between visits, including interruptions. Treatment response cannot be interpreted accurately if the record assumes continuous use when that was impossible. Honest reporting gives the clinician a chance to distinguish inadequate exposure from a genuinely unsuccessful trial.

Start surgical evaluation without waiting for every possible drug

Medication optimization can occur alongside referral to a comprehensive service. The ILAE consensus aims to reduce unnecessary delay and allow suitable patients to learn whether a treatable region can be identified with acceptable risk. The assessment may also improve diagnostic understanding even if no operation is ultimately performed. Jehi et al.: Timing of referral for epilepsy surgery evaluation, ILAE consensus, 2022

A structural finding should be correlated with EEG and clinical evidence, while absence of an obvious lesion does not automatically remove the value of referral. The first objective can be learning which options are feasible. A patient does not need to commit to resection or ablation when arranging an initial assessment. Bernasconi et al.: ILAE structural MRI recommendations and HARNESS protocol, 2019 ILAE EpilepsyDiagnosis: Structural etiologies and imaging

Give non-drug options a defined place

Neurostimulation or professionally managed dietary therapy may be discussed for selected patients. These require assessment of suitability, intended benefit, ongoing work, and adverse effects. Starting every possible intervention at once can make both implementation and interpretation difficult. NINDS: Deep Brain Stimulation NICE NG217: Full guideline, updated January 30, 2025

For an implant, clarify programming and maintenance. For a ketogenic approach, identify the nutrition service and monitoring. China's 2026 neuromodulation guideline considers several outcome domains; fewer events alone does not describe the entire effect on a patient. Each option needs an assessment basis and an identified follow-up team. 中华医学会：神经调控治疗癫痫临床指南2026版，中华医学杂志106(11)，期刊目录及摘要

Agree on how the next trial will be judged

Review seizures together with alertness, learning, work, and ability to manage ordinary activities. Compare event types separately and note potential confounders such as illness, sleep disruption, or missed doses. The observation period depends on the baseline seizure rhythm and adjustment process. A few quiet days do not establish lasting seizure freedom. ILAE/AES TASK1 report: Revisiting drug-resistant epilepsy, 2023

Identify reasons for an earlier review, including unacceptable new symptoms, clear worsening, or a new event pattern. The patient should not wait for the last scheduled visit to report a problem. If a trial does not meet its goal, recording why it was unsuccessful helps the next decision and avoids assuming that every setback means inevitable disease progression.

Ask what information the team wants between appointments. A concise log of event dates and specific adverse effects may be more useful than repeated messages saying the patient feels different. The record should support a clinical interpretation without requiring the patient to make it alone.

Confirm responsibility when arranging treatment in China

CAAE center information can help identify a service, after which the actual department should receive the clinical records. State age, dominant events, previous treatment, and the question to be addressed. Clarify which stage is being arranged: preliminary review, investigations, or a treatment change. An inquiry response does not complete the diagnostic process. 中国抗癫痫协会：第五批一、二级癫痫中心评审结果，2025年9月28日

Where several clinicians participate, identify who maintains the definitive medicine list, responds to abnormal findings, and coordinates care after return home. Request costs for the proposed services and confirm medicine access separately. Preserve original drug names, formulations, and units in translated documents so the local prescriber can verify them directly.

Leave room for review and revision

Before leaving, explain the plan back to the team: what continues now, what happens next, what requires help, and when response will be assessed. If any stage is unclear, request another explanation and an understandable written version. This is a practical requirement for implementing a complex treatment, particularly when care crosses institutions or languages.

At later review, bring together events, adverse effects, and the patient's goals. An unsuccessful change can still supply useful information for choosing another approach. An effective regimen may need updating as age, reproductive plans, organ function, or daily circumstances change. The patient and team should be able to trace each adjustment to an understandable reason.